ClinicalTrials.gg
Active, not recruitingNCT06157892Updated Jul 22, 2026

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

A Phase 2 interventional study of disitamab vedotin and tucatinib in Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma and HER2 Low Breast Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 135 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Triple Negative Breast Neoplasms by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Triple Negative Breast Neoplasms · Pfizer.

Enrollment
13th of 18
54 · median 122
Started
2024
the only one that year
Phase 2
2 of 18
none open now
Registered
17th of 18
by date

Among the 18 studies in Triple Negative Breast Neoplasms by Pfizer, this one is the 13th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 2, and was the 17th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

2 of the 18 studies in Triple Negative Breast Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Triple Negative Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer.

Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2.

This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them.

This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®.

This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

Read the detailed description

This clinical trial is to evaluate disitamab vedotin in combination with tucatinib in subjects with LA/metastatic breast cancer or gastric cancer/GEJC that express HER2. The study has a dose escalation phase evaluating disitamab vedotin plus tucatinib followed by a dose optimization phase. The 2 dose levels identified in the dose escalation phase will be assessed in the optimization phase for both safety and efficacy in HER2-expressing LA/mBC and LA/mGC/GEJC. Once the safety and efficacy profile of disitamab vedotin plus tucatinib has been established and a disitamab vedotin dose with the optimum benefit/risk ratio has been determined the disitamab vedotin plus tucatinib combination therapy will be evaluated in an expansion phase with 4 expansion cohorts in subjects with HER2-low LA/mGC/GEJC, HER2+ LA/mGC/GEJC, HER2-low LA/mBC, and HER2+ LA/mBC.

03

Conditions studied

  • Breast Neoplasms
  • Gastroesophageal Junction Adenocarcinoma
  • HER2 Low Breast Neoplasms
  • HER2 Positive Breast Neoplasms
  • Stomach Neoplasms
  • Triple Negative Breast Neoplasms
  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
  • Advanced Breast Cancer
  • Advanced Gastric Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Gastric Cancer
  • GC
  • GEJ
  • HER2-Low Breast Cancer
  • HER2-Positive Breast Cancer
  • Seattle Genetics
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

This study's enrollment of 54 is close to the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria

  • according to v1.1
  • (ECOG) Performance Status score of 0 or 1

Dose Escalation and Optimization Phase Inclusion Criteria

  • or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma
  • Locally-advanced, unresectable, or stage
  • Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.

Cohort A (-Low Breast Cancer) Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of breast carcinoma
  • Locally-advanced, unresectable, or metastatic stage
  • HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)
  • Prior therapies requirements

    • No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC.
    • Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically
    • Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy
    • Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy disease:

      • Progressed on ≥2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the or metastatic setting OR
      • Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting
    • Participants with HR negative, HER2-low and -positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy.
    • Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.

Cohort B (HER2+ Breast Cancer) Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis breast carcinoma
  • Locally-advanced, unresectable, or metastatic stage
  • HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)
  • Participants must have:

    • Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.
    • Have progression on or after, or intolerant to, T-DXd or other topoisomerase I inhibitor therapies
    • No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC

Cohort C (HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma) Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma
  • Locally-advanced, unresectable, or metastatic stage
  • HER2-low expression defined as IHC 1+ or IHC 2+/ISH-negative determined by most recent local assessment
  • Willing and able to provide archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks
  • Participants must have received:

    • Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease
    • Progression within 6 months of last dose of (neo)adjuvant cytotoxic chemotherapy is considered as 1 for LA/mGC/GEJC
    • Prior anti-PD-(L)1 therapy is allowed
    • No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADC) for LA/mGC/GEJC
  • Must not have received prior treatment with HER2 directed therapy

Cohort D (HER2+ LA/mGC/GEJC) Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma
  • Locally-advanced, unresectable, or metastatic stage
  • HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)
  • Participants must have:

    • Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.
    • Prior T-DXd treatment is allowed
    • Prior PD1 inhibitor therapy is allowed
    • No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mGC/GEJC

Exclusion criteria

Exclusion Criteria:

  • Known to any contained in the drug formulation of disitamab vedotin or tucatinib
  • Prior therapy with ADCs with MMAE payload
  • Prior therapy with tucatinib
  • Active CNS and/or .
  • Participants who have received prior systemic anticancer treatment including agents within 4 weeks prior to first dose of study treatment
  • History of other invasive within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
  • Unable to swallow oral tablets or capsules or any significant GI disease which would preclude the adequate oral absorption of medications
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Dose Escalation - Previously treated advanced GC/GEJC or breast cancer

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Optimization - HER2-low and HER2+ LA/mBC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Optimization - HER2-low and HER2+ LA/mGC/GEJC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Expansion - HER2-low LA/mBC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Expansion - HER2+ LA/mBC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Expansion - HER2-low LA/mGC/GEJC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

  • Experimental
    Dose Expansion - HER2+ LA/mGC/GEJC

    disitamab vedotin + tucatinib

    Drug: disitamab vedotin · Drug: tucatinib

Interventions

  • Given into the vein (IV; intravenous)

    Also known as: RC48, RC48-ADC

  • 300mg given twice daily by mouth (orally)

    Also known as: TUKYSA, ONT-380, ARRY-380

07

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs) in dose escalation phase

    Time frame: Up to 28 days

  2. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Through 30 days after the last study treatment; approximately 5 years

  3. Number of participants with laboratory abnormalities

    Time frame: Through 30-37 days after the last study treatment: approximately 5 years

  4. Number of participants with dose alterations

    Time frame: Through 30-37 days after the last study treatment: approximately 5 years

  5. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment

    The proportion of participants with confirmed response (CR) or partial response (PR) according to RECIST v1.1.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Duration of response (DOR) per RECIST v1.1 by investigator assessment

    The time from start of the first documentation of objective tumor response of CR or PR (that is subsequently confirmed) to the first documentation of progressive disease (PD) per RECIST v1.1, or to death due to any cause

    Time frame: Approximately 5 years

  2. Disease control rate (DCR) per RECIST v1.1 by investigator assessment

    The proportion of participants with stable disease (SD) or confirmed CR or PR according to RECIST v1.1.

    Time frame: Approximately 5 years

  3. Progression free survival (PFS) per RECIST v1.1 by investigator assessment

    The time from the start of any study treatment (or randomization date for participants in dose optimization phase) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.

    Time frame: Approximately 5 years

  4. Overall survival (OS)

    The time from the start of any study treatment (or randomization date for participants in dose optimization phase) to the date of death due to any cause.

    Time frame: Approximately 5 years

  5. Pharmacokinetic (PK) parameter - Maximum concentration (Cmax)

    Time frame: Through 30-37 days after the last study treatment; approximately 5 years

  6. PK parameter - Area under the concentration-time curve to the time of the last quantifiable concentration (AUClast)

    Time frame: Approximately 1 month

  7. Incidence of anti-drug antibodies (ADAs) against disitamab vedotin

    Time frame: Through 30-37 days after the last study treatment; approximately 5 years

08

Study locations

135 sites

Showing the first 100 of 135 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jul 2029, 62 months after the start.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's planned 62 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 6, 2023
StartActual
May 20, 2024
Primary completionEst.
Jul 28, 2029
CompletionEst.
Jul 28, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06157892
Collaborators
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
May 20, 2024
Primary completion
Jul 28, 2029 (estimated)
Completion
Jul 28, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion